We are live on ! Find out more
ESLA icon

Estrella Immunopharma
ESLA

15 hedge funds and large institutions have $1.56M invested in Estrella Immunopharma in 2025 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

700% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 1

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

77% more capital invested

Capital invested by funds: $879K → $1.56M (+$680K)

15% more funds holding

Funds holding: 13 → 15 (+2)

0.64% more ownership

Funds ownership: 2.01% → 2.65% (+0.64%)

Holders
15
Holders Change
+2
Holders Change %
+15.38%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
8
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$212K
2
Marshall Wace
Marshall Wace
United Kingdom
+$106K
3
XT
XTX Topco
Cayman Islands
+$74K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$55K
5
QC
Quadrature Capital
United Kingdom
+$52.6K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$89.3K
2
TRCT
Tower Research Capital (TRC)
New York
-$4.62K
3
SS
SBI Securities
Japan
-$1
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$700K +$55K +29,054 +7%
Renaissance Technologies
2
Renaissance Technologies
New York
$191K +$212K +111,779 +1,046%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$171K +$15.7K +8,318 +8%
Citadel Advisors
4
Citadel Advisors
Florida
$100K +$27K +14,272 +28%
Marshall Wace
5
Marshall Wace
United Kingdom
$87.7K +$106K +56,236 New
XT
6
XTX Topco
Cayman Islands
$77.2K +$74K +39,099 +377%
State Street
7
State Street
Massachusetts
$67.5K +$39.6K +20,900 +94%
QC
8
Quadrature Capital
United Kingdom
$43.3K +$52.6K +27,781 New
BlackRock
9
BlackRock
New York
$41.3K +$4.52K +2,386 +10%
Northern Trust
10
Northern Trust
Illinois
$30.6K +$37.1K +19,624 New
Morgan Stanley
11
Morgan Stanley
New York
$17.3K +$21K +11,097 New
Jane Street
12
Jane Street
New York
$16.3K +$19.8K +10,441 New
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$10K +$12.5K +6,600 New
UBS Group
14
UBS Group
Switzerland
$4.97K -$89.3K -47,160 -94%
Bank of America
15
Bank of America
North Carolina
$16 +$15 +8 +400%
TRCT
16
Tower Research Capital (TRC)
New York
– -$4.62K -4,015 Closed
SS
17
SBI Securities
Japan
– -$1 -1 Closed

ESLA Hedge Fund Activity: Q4 2025 in Review

15 of the 8,252 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q4 2025, worth a combined $1.56M — up 77% from $879K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new ESLA positions and 2 closed out — a net gain of 4 holders — while 8 added to existing stakes and 1 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $212K. The largest seller was UBS Group, cutting an estimated $89.3K.

  • 15 institutional investors held Estrella Immunopharma (ESLA) as of Q4 2025, up from 13 in Q3 2025.
  • Funds reported $1.56M of Estrella Immunopharma stock for Q4 2025, up 77% quarter-over-quarter.
  • 6 funds opened new Estrella Immunopharma positions in Q4 2025 and 2 closed out, a net change of +4 holders.
  • The largest Estrella Immunopharma buyer in Q4 2025 was Renaissance Technologies, an estimated $212K added.
  • The largest Estrella Immunopharma seller in Q4 2025 was UBS Group, an estimated $89.3K sold.

Based on aggregated 13F filings for Q4 2025.